Last reviewed · How we verify

Ceftazidime-avibactam + Sulbactam — Competitive Intelligence Brief

Ceftazidime-avibactam + Sulbactam (Ceftazidime-avibactam + Sulbactam) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam/beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Beta-lactam/beta-lactamase inhibitor combination Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ceftazidime-avibactam + Sulbactam (Ceftazidime-avibactam + Sulbactam) — National University of Singapore. A triple-combination antibiotic that inhibits bacterial cell wall synthesis while protecting against resistance mechanisms through beta-lactamase inhibition.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ceftazidime-avibactam + Sulbactam TARGET Ceftazidime-avibactam + Sulbactam National University of Singapore marketed Beta-lactam/beta-lactamase inhibitor combination Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases
CAZ/AVI CAZ/AVI The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School marketed Beta-lactam/beta-lactamase inhibitor combination Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases
Ceftolozane-tazobactam Ceftolozane-tazobactam National University of Singapore marketed Beta-lactam/beta-lactamase inhibitor combination Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Continuos ceftazidime/avibactam infusion Continuos ceftazidime/avibactam infusion Ivan Šitum, MD marketed Beta-lactam/beta-lactamase inhibitor combination Penicillin-binding proteins (PBPs); serine beta-lactamases
Piperacillin/Tazobactam Intermittent infusion Piperacillin/Tazobactam Intermittent infusion Ain Shams University marketed Beta-lactam/beta-lactamase inhibitor combination Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Ceftazidime-avibactam Ceftazidime-avibactam Qilu Pharmaceutical Co., Ltd. marketed Beta-lactam/beta-lactamase inhibitor combination Penicillin-binding proteins (PBPs); serine beta-lactamases
Piperacillin/Tazobactam Continuous infusion Piperacillin/Tazobactam Continuous infusion Ain Shams University marketed Beta-lactam/beta-lactamase inhibitor combination Penicillin-binding proteins (PBPs); beta-lactamases

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam/beta-lactamase inhibitor combination class)

  1. National University of Singapore · 2 drugs in this class
  2. Ain Shams University · 2 drugs in this class
  3. Merck Sharp & Dohme LLC · 1 drug in this class
  4. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
  5. Southeast University, China · 1 drug in this class
  6. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
  7. Wockhardt · 1 drug in this class
  8. Ivan Šitum, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ceftazidime-avibactam + Sulbactam — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftazidime-avibactam-sulbactam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: